Searched for
GENERIC DRUG MANUFACTURERS
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...
- NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
- India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI AayogIndia's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- India bans 16 fixed-dose drug combinations over safety concernsIn a significant public health initiative, the ban on 16 fixed-dose drug combinations, including various antibiotics and topical formulatio...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...
- Raghuram Rajan's warning to India after Hormuz shock: Build bigger oil reserves, diversify fasterGlobal economic shocks from trade disruptions and geopolitical tensions are reshaping resilience, according to Raghuram Rajan. He stresses ...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Why the ET Most Innovative AI Product Awards 2026 are spotlighting industry-specific innovationThe most impactful AI products of 2026 aren't built to do everything; they're built to solve one problem exceptionally well. The ET Most In...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- Drug companies directed to step up vigil on adverse reactionsIndia's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...
Load More
